
What to Watch as Retension Pharmaceuticals Prices on Nasdaq
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) is expected to list on 2026-10-09, and the company has not disclosed a price range. The IPO is priced, with 3,300,000 shares offered and a disclosed market cap of $41.25 million. The setup is straightforward: shareholders should watch whether RTN-001’s Phase 2b data can support a larger hypertension story, but the stock still carries classic single-asset biotech risk.










